Saturday, May 31, 2008
The Westin Seattle  ♦  Grand Ballroom I  ♦  Seattle, Washington
6:00—6:30 am  ♦  Registration & Breakfast
6:30—7:45 am  ♦  Program
Download Program Brochure

Register Now

Statement of Need
Although statin therapy can substantially reduce cardiovascular risk in patients with elevated low-density lipoprotein cholesterol (LDL-C), considerable residual risk remains despite treatment. This is likely attributable to a mixed dyslipidemic state characterized by low levels of high-density lipoprotein cholesterol (HDL-C), hypertriglyceridemia, and a preponderance of small dense LDL particles. Raising HDL-C may offset some of this residual risk.

Epidemiologic studies have shown low HDL-C to be an independent and predictive risk factor for coronary heart disease (CHD). Evidence suggests that the cardiovascular event rate is reduced by at least 1% for each 1% increase in HDL-C. This effect is statistically independent of the nearly 1% cardiovascular event rate reduction for each 1% reduction in LDL-C; thus, for moderate lipid changes, the combined effects are additive.

High-density lipoprotein attenuates plaque progression and reduces CHD risk. These effects are attributable to reverse cholesterol transport, antioxidant properties that reduce the atherogenicity of LDL, inhibition of adhesion molecule expression on endothelial cells, and regulation of nitric oxide production.

This symposium will discuss the role of HDL in lipid metabolism and atheroprotection. Emerging data on HDL-C-raising therapeutics as a promising approach to reducing cardiovascular risk in patients with mixed dyslipidemia also will be presented.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Course Chair
Jay W. Heinecke, MD
Professor of Medicine
Division of Metabolism, Endocrinology, and Nutrition
Department of Medicine
University of Washington School of Medicine
Seattle, Washington

Faculty
Eliot A. Brinton, MD
Associate Professor of Medicine
Director Metabolism Section
Cardiovascular Genetic
University of Utah School of Medicine
Salt Lake City, Utah

Bruce Gregory Brown, MD, PhD
Professor Emeritus
Division of Cardiology
University of Washington School of Medicine
Attending Physician
University of Washington Medical Center
Seattle, Washington

Agenda

6:00 - 6:30 am   Registration and Dinner
6:30 am   Welcome and Introductions
Jay W. Heinecke, MD
6:30 - 6:50 am   The Mixed Dyslipidemic State: Underlying Role of HDL in Lipid Metabolism and Atheroprotection
Jay W. Heinecke, MD
6:50 - 7:10 am   Reducing Residual Cardiovascular Risk: Rationale for Raising HDL-C in the Mixed Dyslipidemic State
Bruce Gregory Brown, MD, PhD
7:10 - 7:30 am   HDL-C-Raising Therapies: The Forefront to Optimizing CV Risk Reduction
Eliot A. Brinton, MD
7:30 - 7:45 am   Panel Discussion

Target Audience
This activity is intended for physicians, physician assistants, pharmacists, nurses, and registered dietitians interested in cardiovascular disease. In accordance with PhRMA guidelines, this program is intended for healthcare professionals only.

CME credit provided by The National Lipid Association.

Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Lipid Association designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts Category 1 credit from AOACCME, Prescribed Credit from AAFP, and AMA PRA Category 1 Credit ™ from organizations accredited by AACME.

CE credit provided by the Institute for Continuing Healthcare Education.

Nurses
The Institute for Continuing Healthcare Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity offers 1.2 contact hours to participating nurses. This credit may be applied toward licensure requirements in those states that recognize American Nurses Credentialing Center's Commission on Accreditation (ANCC-COA) accredited providers. Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA. Jacqueline Dawson, MSN, RN, is the nurse planner for this activity.

Dietitians
This program is cosponsored by the Institute for Continuing Healthcare Education and the National Lipid Association. The Institute for Continuing Healthcare Education, provider number IN003, is a Continuing Professional Education (CPE) accredited provider with the Commission on Dietetic Registration (CDR) from March 28, 2007 to March 27, 2010. Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.0 continuing professional education units (CPEUs) for completion of this level 2 program. Continuing Professional Education Provider Accreditation does not constitute endorsement by the CDR of a provider, program, or materials.

Pharmacists
This program is cosponsored by the Institute for Continuing Healthcare Education and the National Lipid Association. The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is acceptable for 1.25 hours (0.125 CEU) of continuing education credit in states that recognize ACPE-accredited providers (ACPE ID no. 781-999-08-026-l01-p).

Faculty Disclosure Statement
The National Lipid Association and the Institute for Continuing Healthcare Education adhere to ACCME essential areas and policies regarding industry support of continuing medical education. Disclosure of faculty and commercial relationships, if any, will be disclosed in the syllabus.

Supported by an educational grant from Merck & Co., Inc.